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Biodegradable liposome-encapsulated hydrogels
for biomedical applications: a marriage of
convenience
Santiago Grijalvo,a,b Judith Mayr,c Ramon Eritjaa,b and David Díaz Díaz*a,c
Hydrogels are hydrophilic three-dimensional networks with demonstrated potential for medical and
pharmaceutical applications. Speciﬁcally, biopolymer-based hydrogels oﬀer certain advantages over syn-
thetic polymers in terms of biocompatibility and biodegradability. Because of their inherent properties,
hydrogels are able to eﬃciently encapsulate and liberate in a controlled release manner, diﬀerent hydro-
phobic and hydrophilic therapeutic molecules, including nucleic acids, proteins and antibodies. Several
strategies have been reported in the literature to minimize the potential burst release of encapsulated
drugs, thus preventing their local accumulation and consequent toxic responses. Within this context, lipo-
somes embedded in hydrogels have emerged as an attractive strategy to reduce this undesirable eﬀect.
This tutorial review covers a selection of the most promising cationic, neutral and anionic biopolymer-
based hydrogels containing liposomes, niosomes or vesicles for drug delivery or tissue engineering
applications.
1. Introduction
Over the past few decades, synthetic progress towards fabrica-
tion of new polymeric materials that respond to external
stimuli (e.g., temperature, light, pH)1–4 has stimulated the
development of novel approaches for drug delivery,5,6 tissue
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engineering7 and nanobiotechnology.8,9 This environmental
responsiveness triggers major changes in both the physico-
chemical and self-assembling properties of such macro-
molecular systems, which can be used to favour the
encapsulation/release of active molecules. Indeed, there are
numerous examples in the literature where synthetic polymers
have been used either as therapeutic macromolecules or as
drug delivery vehicles upon combination with small
drugs.10–12
However, for real applications, synthetic polymers must
fulfill a series of requirements such as being non-toxic, non-
immunogenic and water-soluble together with safe excretion
properties, which in most cases become very diﬃcult chal-
lenges. It is at this point where biocompatible and biodegrad-
able natural polymers represent a versatile and renewable
alternative to synthetic polymers. In general, biopolymer-based
materials are mainly made of polysaccharides and are usually
key components in food industrial formulations acting as
emulsifying, gelling and/or stabilizing agents.13 Furthermore,
they have also been proven to be promising materials for bio-
medical applications including drug delivery and regenerative
medicine.14–17
1.1. Hydrogels
Polymeric hydrogels are hydrophilic 3D polymer networks
capable of absorbing large amounts of water in a similar way
to body tissues. This property allows hydrogels to encapsulate
therapeutic molecules and protect them from rapid
degradation,18–20 making them useful materials for pharma-
ceutical and medical purposes.18,19
In 1960, Wichterle and Lim21 reported the use of poly-2-
hydroxymethacrylate (PHEMA)-based hydrogels for contact
lens applications. Since then, the extensive research carried
out in the field of hydrogels has allowed the development of
not only polymeric networks based on synthetic polymers
such as poly(vinyl alcohol),22,23 poly(ethyleneimine)24 and
poly(ethylene oxide),25 among others, but also based on
natural polymers such as alginate26 and chitosan.27
Another important feature of many polymeric hydrogels is
their ability to release entrapped therapeutic molecules in a
well-controlled manner. This property is usually governed by
passive diﬀusion mechanisms and can also depend on
additional factors (e.g., cross-linking degrees, hydrogel mesh
sizes, stimuli-sensitive hydrogel capacity, etc.). One major
aspect to take into account during release experiments is the
possibility of obtaining undesired initial liberation of the drug
immediately upon contact with the release medium. Although
this undesirable eﬀect could be positive in exceptional thera-
peutic strategies, it usually causes an unexpected in vivo tox-
icity due to the local presence of large amounts of drug (“dose-
dumping”). Such a process is known as burst release eﬀect.28
Although the exact mechanism and prediction of burst
release in hydrogel/drug systems has not been elucidated
yet,29,30 several strategies have been reported to minimize this
eﬀect. These include, for example, increasing the cross-linking
density of the material, coating additional drug-free layers or
using drug surface extractions prior to in vivo usages.31–33
1.2 Hydrogel classification and basic structure
Hydrogels are classified according to several characteristics.
For example, they can be classified on the basis of ionic
charges (neutral, anionic, cationic or ampholytic hydrogels),
the nature of side groups (e.g., neutral or ionic), their physical
structure (e.g. amorphous, semi-crystalline, hydrogen-bonded
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structures, super-molecular structures and hydrocolloidal
aggregates), the crosslink nature (e.g. chemical or
physical) and their preparation method (e.g., homo- or co-
polymers).34
Hydrogels can also have many diﬀerent physical forms and
have been used in varying therapeutic applications. Some
examples include solid molded forms (e.g. contact lenses),
pressed powder matrices (e.g. pills and capsules), beads (e.g.,
drug delivery), microparticles (e.g. wound treatments), coatings
(e.g. implants or catheters) and membranes or sheets (e.g.,
a reservoir in a transdermal delivery patch).
An important issue to consider for drug delivery appli-
cations is to understand the transport mechanisms of the drug
through the hydrogel matrix, which is usually governed by
several parameters such as polymer composition, porosity,
degradation rate, size and gel swelling.35 The mesh size is an
important property that is related with degradability, mechan-
ical strength and drug diﬀusion. Thus, as the gel swells, its
mesh size increases and thus facilitates the corresponding
drug release in solution. As a consequence, a good number of
factors has to be considered and this requires a high degree
control over some properties when designing hydrogels.
Hence, hydrogel crosslinking degree, stimuli (pH, tempera-
ture) or monomer chemical structures are important para-
meters to design appropriate diﬀusion patterns of model
drugs.36 Most hydrogels have the possibility of tuning their
mesh sizes with varying dimensions and patterns that can
range from micrometers to nanometers (5 to 100 nm) approxi-
mately in their swollen state. Specifically, microgels have been
designed as novel platforms for both local sustained drug
release and their ability to mimic the native tissue mechanical
properties (3D-cell culture environment) as well as a platform
for local protein release. This application has allowed both a
rational design and the development of microfabrication
strategies that have helped to provide new insights into
regeneration and tissue repair applications.37
Nanogels have also become promising materials to be
mostly used in systemic drug delivery applications. Moreover,
they have shown certain advantages over other existing drug
delivery systems. Therefore, a decrease in the hydrogel size
may produce a faster response for gel swelling and thus
increasing the material response and, consequently, the antici-
pated drug action.38 The recent advances of click chemistries
aﬀording the eﬀective introduction of targeting ligands com-
bined with the use of either polysaccharide-based crosslinked
agents or cross-linkers containing biodegradable linkages have
allowed the preparation of functional nanogels with narrow
size distributions that have facilitated both cellular uptake and
have avoided undesirable aggregation processes.39,40 Such
control of microgel and nanogel properties has allowed exten-
sive research in the development of synthetic strategies for the
preparation of such materials. For example, a variety of pro-
cesses like photolithographic, microfluidic techniques, micro-
molding methods as well as the use of heterogeneous
solution, aqueous homogeneous gelation, spray drying
methods, chemical crosslinking of dextranes or heterogeneous
radical polymerizations are the most representative methods
that have been described and revised in the literature.41
1.3. Liposomes and preparation methods
Liposomes (self-assembled lipid vesicles) are one of the most
used nanosystems to encapsulate drug molecules. Because of
their nanometer size, these kinds of non-viral carriers have
become one of the most studied drug delivery systems for
clinical applications to date.42–44 Since their beginning in the
60s, the field of liposomes has undergone a major change with
respect to the development of novel responsive vesicles with at
least one lipid bilayer45,46 and their applications in hyper-
thermia processes for cancer treatment.47,48
A good number of encapsulation strategies where lipo-
somes are used have been reported to date. For instance, an
elegant and recent approach consists of introducing diﬀerent
types of nanoparticles (e.g., gold and silver nanoparticles,
SPIOs or lipid vesicles) and obtaining the corresponding “lipo-
some–nanoparticle” hybrids using liposomes as templates.49,50
The methodology involved in the synthesis of these constructs
has helped us to obtain systems that have enhanced their bio-
compatibility and colloidal stability. Other methods have also
been developed for the preparation of “liposome–virus”51 and
“liposome–quantum dot” hybrids.52 These novel approaches
have allowed the use of liposomes in therapeutic, diagnostic
and theranostic applications.
There is a wide range of possibilities for preparing lipo-
somes42 (Table 1). Therefore, depending on the procedure, pro-
perties like lamellarity, size, morphology and composition of
liposomes can be diﬀerent. Although most of these processes
are standardized and optimized for laboratory scale and prepa-
ration is straightforward, there are some limitations like the
length of procedures, polydispersity and low drug encapsula-
tion, which are the main drawbacks for conventional liposome
preparation methods.
To address these issues, more eﬃcient novel procedures
have been described. Conventional liposome preparations are
as follows: (a) the thin-lipid film hydration approach was the
first methodology developed and the most common method
for preparing liposomes.53 Thus, multilamellar (MLVs), giant
unilamellar (GUVs) or small unilamellar (SUVs) vesicles may
be obtained which are diﬀerent from each other according to
the preparation technique used.54,55 However, some limit-
ations can clearly be identified using the technique such as
possible liposome degradation upon sonication, hetero-
geneous size distribution, high temperature exposure or low
drug encapsulation eﬃciencies. (b) Reverse-phase evapor-
ation56 is another technique that consists of obtaining suspen-
sion of large unilamellar vesicles by removing the organic
solvent under reduced pressure. This technique involves water-
in-oil formation from a mixture of surfactants and lipids as
well as an aqueous solution containing the drug. The presence
of organic traces in the final formulation could influence the
vesicle stability. (c) The solvent injection technique is another
conventional method used to prepare liposomes which is
based on injection of phospholipids dissolved in an organic
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solvent like ether or ethanol into an aqueous phase that con-
tains a particular drug and is maintained at a temperature
above the organic solvent boiling point.57 Although the advan-
tage of this technology is the ability to control the vesicle size,
the presence of organic solvent traces in the final formulation,
dilution of the liposomes represent a clear disadvantage for
this type of approach which reduces the eﬃciency of this
approach.
More recently, novel methods have been described for pre-
paring liposomes. Microfluidic technology has been used for
preparing monodisperse liposomes on both laboratory and
clinical scales and are easily reproducible.58,59 Optimizing the
parameters such as the flow rate ratio or the size of micro-
channels provides liposomes with varying and more accurate
control sizes. Eﬃcient liposomal distribution, higher encapsu-
lation eﬃciencies and the reduced loss of reagents are con-
sidered as being the advantages of this process. However, this
microfluidic device fabrication may be considered a diﬃcult
and complex since it requires optimization of multiple fluid
inputs and diﬀerent fluid phases; as a consequence, liposome
scale-up production becomes challenging.
On the other hand, there are also techniques that have
been developed on an industrial scale which include super-
critical reverse phase evaporation,60 which employs supercriti-
cal CO2 in order to dissolve phospholipids. From an industrial
point of view, the use of CO2 creates an environmentally-
friendly process and is a good organic solvent substitute for
preparing liposomes as it is non-toxic and not inflammable.
Moreover, this technology often yields higher encapsulation
eﬃciencies compared with conventional procedures. Despite
these advantages, this method uses elevated pressures (around
20–25 MPa) and temperatures (333 K). Spray drying,61 mem-
brane contactor technology62 or crossflow injection63 tech-
niques are other alternative methods that have also been
described for industrial scale-up in liposome production
because of their cost eﬃciency and short-duration processes.
The advantages and disadvantages are both covered in Table 1.
Liposome-based technology has revealed serious shortcom-
ings such as instability, a short life and rapid degradation. To
address these issues, extensive research has been carried out
in order to increase and improve its eﬃcacy. In addition to the
synthesis of second generation liposomal drugs described
above, the integration of liposomes and polymeric matrices
(“liposomes-in-hydrogels” or lipo-beads) may represent a prom-
ising approach for minimizing burst release and improving
tissue localization, especially in topical drug delivery appli-
cations including wound therapy and sustained drug delivery.
The nature of the polymer may also modify the properties of
the encapsulated liposomes (membrane integrity and mechan-
ical stability). This property, together with the liposome con-
centration, lipid composition as well as liposome interaction
with hydrogels, which are also related to the swelling/deswel-
ling properties of the hydrogels, may aﬀect their rheology pro-
perties64 and thereby modulate the release of a therapeutic
drug.
The preparation methods described for liposomes-in-hydro-
gels are mainly governed by incubating the anticipated lipo-
somes with the pre-formed hydrogel beads. Although the
encapsulation process of the resultant liposomes within the
polymeric matrix takes place and has been experimentally
Table 1 Liposome preparation methods and main features
Conventional methods
Preparation method
Particle size
(nm) Advantages Disadvantages Ref.
Thin-lipid film hydration 100–1000 Most widely used method Low encapsulation eﬃciencies, sonication,
temperature exposure, heterogeneous
size distribution
53
Reverse-phase evaporation 100–1000 High encapsulation eﬃciency Organic solvent traces 56
Solvent injection
(ether or ethanol)
70–200 Ability to control vesicle size Dilution of liposomes, heterogeneous
population, use of high temperature
57
Novel methods
Preparation method
Particle
size
(nm) Advantages Disadvantages Ref.
Microfluidic technology 100–300 Synthesis of monodisperse liposomes, high
encapsulation eﬃciency
Fabrication could be complex
and needs optimization
58 and 59
Supercritical reverse
phase evaporation
100–1200 Environmentally-friendly process, high encapsulation
eﬃciencies
Elevated pressures and
temperatures
60
Spray drying 100–1000 Control over particle formation, easily translated to
large-scale production
Expense and time-required 61
Membrane contactor
technology
∼100 Liposomes have homogeneous and small size, high
encapsulation eﬃciency, simplicity for scaling-up
Hydrophilic drug encapsulation
needs optimization
62
Crossflow injection ∼50 Liposomes of defined size Vesicle stability due to residual
solvent
63
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confirmed, some concerns regarding phospholipids self-
assembling and bilayer stabilities should also be considered.65
This combination has successfully allowed the incorporation
of a wide number of liposomes into both synthetic and natural
polymer-based hydrogels, obtaining the resultant stimuli-
responsive hybrid materials.
Although a number of synthetic polymer-based hydrogels
containing liposomes have been described to date,66–68 many
of them may present limitations for clinical applications due
to cytotoxic eﬀects. Thus, the use of biocompatible and bio-
degradable hydrogel matrices has gained increased scientific
attention over the last decades. The first liposomal biohydrogel
system was described by Weiner and co-workers in 1985.69 In
this work, a liposomal formulation containing two peptide
hormones (insulin and growth hormone) was introduced into
a collagen gel matrix. Slow release rates of the hormones were
obtained when this liposome–collagen hybrid was used. Fur-
thermore, the authors also observed important diﬀerences in
the release when comparing these liposomal formulations in
the absence and in the presence of the hydrogel. Since then
the “liposomes-in-hydrogels” strategy has emerged as a prom-
ising approach for obtaining self-regulated drug delivery
systems.
2. Liposomes in biopolymer-based
hydrogels
In principle, the combination of liposomes and biopolymer-
based hydrogels could oﬀer important advantages with respect
to synthetic polymers for biomedical applications70 by improv-
ing both drug formulation stabilities and drug administration
routes.
This review describes the most relevant examples of lipo-
somes encapsulated in biopolymer-based hydrogels for bio-
medical applications. The use of synthetic polymers66–68
instead of biopolymers is out of the scope of this review. The
manuscript is organized in subsections according to the type
of biopolymer used for the preparation of the hydrogel matrix.
Particular emphasis is given to the characterization of these
hybrid materials and the release profile of encapsulated model
drugs or therapeutic molecules (Fig. 1).
2.1. Chitosan
Chitosan is a cationic, biodegradable, biocompatible and
mucoadhesive biopolymer composed of randomly distributed
β(1 → 4)-linked D-glucosamine (deacetylated unit) and N-acetyl-
D-glucosamine (acetylated unit). Chitosan-based hydrogels are
one of the most studied systems for applications in biomedical
fields such as enzyme immobilization, tissue engineering,
wound therapy and drug delivery.27,71–73
In 2002, Leroux and co-workers74 described for the first
time the encapsulation of liposomes within chitosan poly-
meric matrices. Rheological experiments showed that the
presence of liposomes in a chitosan-β-glycerophosphate for-
mulation slightly increased both the viscoelastic properties
and the gel strength. Additionally, a significant increase in the
in vitro release time was achieved when liposomes containing
model hydrophilic molecules (i.e., 5- and 6-carboxyfluorescein)
were embedded in the hydrogel matrix. It is worth mentioning
that sustained drug liberation over 2 weeks was obtained with
this liposomal formulation. As a control experiment, the time
of the release in the absence of liposomes was also evaluated,
confirming the complete drug release within 24 h.
Among the variables that can aﬀect control release pro-
cesses, liposomal composition, vesicle size and surface charge
have been studied in order to find a suitable liposomal formu-
lation for application in wound therapy. For example, Škalko-
Basnet and co-workers carried out detailed studies using
two pH-dependent rhodamine derivatives as model drugs
embedded into chitosan-based hydrogels.75 The results
demonstrated that liposome sizes had a minor eﬀect on the
in vitro drug release whereas both liposomal surface charge
and drug lipophilicity considerably aﬀected the release
kinetics.
Similar systematic studies have been recently carried out by
Ladavière and co-workers.76 Phosphatidylcholine liposomes
made of a mixture of DPPC and a fluorescent lipid at a
99 : 1 molar ratio, were mixed in chitosan solutions (Fig. 2A).
This mixture did not aﬀect the final process of the hydrogel
formation and rheological studies confirmed that introducing
phosphatidylcholine liposomes within the chitosan matrix did
not aﬀect the viscoelastic properties of the system either.
Additionally, fluorescent liposomes were introduced within the
polymeric network and the complexes were characterized by
fluorescence and cryo-SEM microscopy. In vitro release experi-
ments using carboxyfluorescein as a model drug showed
delayed drug release compared to that in the absence of the
liposomes (Fig. 2B).
Rouini and co-workers77 performed both in vitro and in vivo
experiments with a series of radiolabelled liposomes
embedded into chitosan-β-glycerophosphate hydrogels. The
studied vesicles varied either on the acyl chain length (DMPC,Fig. 1 Schematic concept covered by this review.
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DPPC or DSPC) or on the surface charge (DSPG and DOTAP).
The authors found that liposomes made of DSPC showed
better release profiles than the other ones when injecting the
corresponding liposomal formulations in mice models. Fur-
thermore, liposomes made of DSPC showed a higher transition
temperature, which generated stronger bilayers than the other
liposomes tested. This stability eﬀect induced liposome reten-
tion for a long period of time in the peritoneum after
injection. An opposite eﬀect was observed for liposomal
dispersions made of negatively charged DSPG liposomes.
These vesicular carriers left the peritoneum rapidly after injec-
tion. Interestingly, the authors were able to prolong this lipo-
somal release at the highest level when entrapping the same
vesicular dispersions within chitosan hydrogels. This change
in the release behaviour was attributed to the presence of
interactions between the matrix polymer and phospholipids.
Besides studying the parameters that can govern control
release processes such as size, charge or lipid composition by
using model drugs, the use of liposomal formulations
entrapped into chitosan hydrogels containing either thera-
peutic molecules or macromolecules has been successfully
reported in the last few years. For example, Škalko-Basnet and
co-workers78,79 were able to entrap Mupirocin, a promising
antimicrobial drug, in phosphatidylcholine liposomes of
various sizes. Cytotoxicity and both in vitro and in vivo experi-
ments were also reported. The results confirmed an antimicro-
bial potential activity against Staphylococcus aureus together
with an enhancement in wound healing over 28 days in vivo.
Furthermore, a superior bio-adhesiveness was also exhibited
when compared to conventional treatments in burn wound
healing rat models.
Ofloxacin, a second-generation fluoroquinolone derivative
used for treating severe eye infections, usually suﬀers major
drawbacks (e.g., necessity of frequent administration, low solu-
bility) when administered in solution. However, Hosny and co-
workers80 have recently shown promising therapeutic eﬀects
(i.e., prolonged release time and improved stability) when
carrying out in vitro transcorneal permeation assays by using
chitosan-based hydrogels as carriers.
Certain hydrogels are injectable due to the fact that they
can exist in a low-viscosity form either prior to or during injec-
tion.81 This property has been applied for site-specific drug
delivery applications. Interesting results were obtained in the
case of measuring the release kinetics of doxorubicin (Dox),
which was encapsulated in the interior of small unilamellar
vesicles from a hydrophobically modified chitosan (hmC) gel
(Fig. 3).70 The connection between the liposomes and the
hydrogel network was achieved by hydrophobic interactions
between polymer chains and liposome bilayers. Steady-shear
rheology studies confirmed the properties of injectability of
the liposomal Dox–hmC hybrid systems (Fig. 3A). The results
showed that the combined system of liposomes and hmC
hydrogel could act as an eﬃcient barrier, promoting sustained
release of the drug over a week (Fig. 3B).
Recently, Duﬀy and Ruiz-Hernández82 have reported the
use of chitosan-β-glycerophosphate matrices as carrier systems
for local chemotherapy treatment. In this work, a mixture of
non-toxic thermosensitive liposomes made of dipalmitoyl
phosphatidyl choline (DPPC), monostearoyl-phosphatidyl
choline (MSPC) and distearoylphosphatidylethanol-aminepoly
(ethylene)glycol (DSPE-PEG2000) at a 85.3 : 9.7 : 5.0 ratio,
respectively, was used to entrap Dox (Fig. 4). Interestingly, the
cumulative Dox release from the polymer network was
enhanced after using hyperthermic pulses, which reduced
Fig. 2 (A) Schematic representation and the chemical structure of ﬂu-
orescent liposomes in chitosan hydrogels. (B) Carboxyﬂuorescein cumu-
lative release percentage for chitosan hydrogels in the absence (open
symbols) and in the presence (full symbols) of liposomes. Adapted with
permission from ref. 76. Copyright © 2015 Elsevier.
Fig. 3 (A) Pictures of an injectable liposome gel at rest (top) and under
shear (bottom). Modiﬁed chitosan hydrogels are represented in blue and
the grafted hydrophobes in red. (B) Cumulative release of Dox through
modiﬁed chitosan matrices. Dox release from hydrogels containing lipo-
somes is slower than those in the absence of liposomes. Adapted with
permission from ref. 70. Copyright © 2012 American Chemical Society.
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dsDNA levels when compared to the corresponding non-
pulsed samples (Fig. 4B and C).
Besides using chitosan hydrogels for the release studies of
low molecular weight molecules, the release of macrobiomole-
cules has also been studied. In this context, ovalbumin (OVA)
and the immunopotentiator Quil A (QA) were entrapped into
both cationic nanosized liposomes and cubosomes, a more
stable lipid vesicle system.83 A nice sustained release of the
model antigen (OVA) was observed in vivo when liposomes
were entrapped into chitosan hydrogels. Although OVA-specific
antibodies were detected, the system evidenced certain
instability even for cubosomes. Unfortunately, OVA and QA in
solution forms exhibited similar immunogenicity responses to
liposomes when the same thermosensitive chitosan hydrogels
were used.
Chitosan-based hydrogels containing liposomes have been
further modified by adding additional biopolymers in order to
generate novel bio-systems capable of both protecting liposomal
formulations and obtaining prolonged, controlled release
kinetics. For example, Peptu and co-workers84 prepared hydro-
gels made of a mixture of chitosan and gelatin. Both biopoly-
mers were crosslinked with glutaraldehyde and sodium/
sulphate tripolyphosphate. A hydrophilic model drug (calcein)
was encapsulated in both small unilamellar vesicles (SUVs)
and multilamellar vesicles (MLVs) and finally entrapped
within the mixture of the aforementioned hydrogels with vari-
able compositions. In vitro control release experiments showed
improvement in the liposomal stability together with pro-
longed calcein release from several days to weeks. Interestingly,
chitosan/gelatin hydrogels containing MLVs led to better sus-
tained and prolonged release kinetics than those obtained
with polymeric matrices containing SUVs. Although the
calcein release mechanism from the two biopolymer-based
hydrogels is complex, the authors suggested the existence of
two steps until the drug reaches the hydrogel surface, consist-
ing of liposome diﬀusion through the matrix followed by
destabilization of the vesicles produced before leaving the
hydrogel.
2.2. Gelatin
Gelatin is a biodegradable, thermally denatured protein
derived from collagen, a natural protein that is present in
mammal tissues, tendons and ligaments. The isoelectric point
of gelatine at physiological pH can be modified during its
extraction to aﬀord either positively charged basic gelatin
(classified as gelatin A) by acidic treatment, or negatively
charged acidic gelatin (classified as gelatin B) by alkaline treat-
ment. This versatility has allowed the preparation of numerous
polyplexes for drug delivery by combination with a variety of
charged biomolecules.85–87
There are several examples in which gelatin-based hydro-
gels have been used for controlled release studies. In most
cases, gelatin hydrogels have been chemically modified by
adding cross-linking agents such as glutaraldehyde84 and
genipin,88 among others,89–91 in order to modify the drug
release rates. However, the encapsulation of liposomes in
gelatin hydrogels has been only scarcely explored. In 2009,
Raghavan and co-workers92 described the entrapment of vesi-
cles made of sodium oleate (NaOA) in a gelatin matrix at
slightly alkaline pH (8.3). It is well-known that these vesicles
have the property to self-assemble into spherical micelles in
solution at a pH higher than 10 (Fig. 5A and B).93 Interestingly,
Fig. 4 (A) Pictures of hybrid chitosan hydrogels before (20 °C) and after
(37 °C) gelation. (B) Liposome release through the polymeric matrix by
using a hyperthermia approach. (C) Cumulative Dox release proﬁles
from the polymeric matrix with and without a 1 h pulse at 42 °C.
Adapted with permission from ref. 82. Copyright © 2014 Wiley-VCH.
Fig. 5 (A) Micellar movement through gelatin hydrogels due to
diﬀusion of pH 10 buﬀer. NaOA vesicles are converted into NaOA
micelles at diﬀerent times. (B) Pictures of gelatin hydrogels, NaO vesicles
and gelatin-loaded with NaOA vesicles. (C) Calcein release from pH-
responsive hydrogels. The release was more gradual at pH 8.3 than at
pH 10. Adapted with permission from ref. 92. Copyright © 2009 Ameri-
can Chemical Society.
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this pH-responsive property was observed when these vesicles
were loaded into gelatin hydrogels at pH 8.3 and 10. When
calcein was embedded into the liposomes, a more gradual
release was observed at pH 8.3, compared to the control. As
expected, this release was accelerated when the pH solution
was raised to pH 10 (Fig. 5C). This rapid release was attributed
to vesicle-to-micelle transitions, which reduced the transport
resistance in the drug diﬀusion from the hydrogel to the
external release solution.
2.3. Dextran
Dextran is a neutral, biodegradable, branched polysaccharide
made of glucose molecules composed of chains of varying
lengths (from 10 to 150 kDa). From a structural point of view,
the native straight chain consists of α-1,6-glycosidic linkages
between glucose molecules whereas branches begin from
α-1,2, α-1,3 and α-1,4 linkages. Dextran-based hydrogels have
been fine-tuned either by adding cross-linking agents such as
lactic acid,94 diisocyanate,95 polyamines,96 a mixture of biopoly-
mers97 or by free radical polymerization using glycidyl methacry-
late.98 These kinds of hydrogels have been explored in a wide
variety of biomedical applications such as detection of small
molecule drugs99 and non-viral carriers for proteins.100
De Smedt and co-workers reported the coating of hydroxy-
ethyl methacrylated dextran (dex-HEMA) nanogels with
SOPC/DOTAP liposomes by either using UV polymerization101
or by electrostatic interactions between dextran’s charged
surface and oppositely charged lipid vesicles.102 DLS and AFM
measurements of dex-HEMA nanogels containing lipid par-
ticles showed sizes of ca. 350 nm. To confirm the presence of
the lipid composition in dex-HEMA nanogels, Triton-X100
(TX100) was added to the dispersions in order to solubilize the
lipid coating. This resulted in a mixture of naked dex-HEMA
and micelles that were also detected by DLS experiments. Alter-
natively, removal of the lipid coating in dex-HEMA nanogels
was corroborated by AFM measurements. As illustrated in
Fig. 6, nanogel particles without liposomes (Fig. 6B) displayed
a softer surface than those containing SOPC/DOTAP liposomes
(Fig. 6A). DLS measurements revealed a relationship between
cross-linking density and stability of the particles. Specifically,
highly substituted dex-HEMA nanogels showed better stabi-
lities in PBS buﬀer at 37 °C, which ranged from few days to 2
weeks. However, poorly substituted dextran hydrogels were
unstable and degraded quickly. Finally, transfection studies
were successfully carried out and confirmed that dex-HEMA
nanogels containing SOPC/DOTAP liposomes were able to
impart cellular uptake in VERO-1 cells, showing potential as
drug delivery carriers (Fig. 6C).101
Another interesting application involving covalently cross-
linked dextran-polyethyleneglycol (Dex-PEG) hydrogels was
developed by Kros and co-workers.103 This method is based on
the formation of giant unilamellar vesicles (GUVs) by using
Dex-PEG hydrogels which were incorporated on glass surfaces
via a Michael addition reaction. Once Dex-PEG polymer was
deposited on the surface, several lipid mixture compositions
were added following the film-hydration method by using both
PBS and HEPES potassium chloride saline buﬀers in order to
study the eﬀect of ionic strength on the vesicle growth. Inter-
estingly, a nice correlation between Dex-PEG cross-linking
density and vesicle size distributions was observed. In prin-
ciple, the possibility of being able to grow and vary the size of
the vesicles could make this system a promising tool to be
used in numerous applications such as drug delivery and
molecular recognition, among others.
2.4. Pullulan
Fig. 6 (A) AFM images of SOPC/DOTAP coated dex-HEMA nanogels. (B)
AFM images of native dex-HEMA nanogels when TX100 was added to
the dispersion displayed in panel (A). (C) Image of VERO-1 cells incu-
bated with lipid coated dex-HEMA nanogels. Adapted with permission
from ref. 101. Copyright © 2005 American Chemical Society.
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Pullulan is a highly water-soluble biodegradable poly-
saccharide made of maltotriose repeating units, containing
α-(1 → 4) and α-(1 → 6) glycosidic linkages in a 2 : 1 ratio. This
polysaccharide has been widely used in coating applications104
and drug delivery.105
Akiyoshi and co-workers106 synthesized stable cholesterol-
pullulan (CHP) nanogels of ca. 30 nm in size based on specific
hydrophobic interactions107 between cholesteryl moieties and
pullulan biopolymer in aqueous solutions (Fig. 7).108,109 So
formed CHP particles showed also the ability to form stable
hydrogels in the presence of liposomes and using PEG as a
cross-linker (Fig. 7A). The hydrogel could help us to increase
the colloidal stability, thereby avoiding undesirable aggrega-
tion processes. The final CHP hybrid systems were character-
ized in terms of TEM microscopy and particle-tracking micro-
rheology which indicated that both the strength and the gela-
tion time could be tuned depending on the CHP : liposome
ratio. Specifically, liposomal release from CHP nanogels was
monitored by coating the aforementioned CHP with liposomes
based on a mixture of dimyristoylphosphatidylcholine (DMPC)
and cholesterol at a 3 : 1 ratio. The authors observed a sequen-
tial dual release profile in which CHP nanogel was first liber-
ated followed by the release of nanogel-coated liposome
complexes under physiological conditions, which was fully lib-
erated within 40 days. Interestingly, a clear dependence of the
release with the pH was observed between pH 7.4 and 8.0 in
which the liposome complex was released within 20 days
(Fig. 7B).
2.5. Hyaluronic acid
Hyaluronic acid (HA) is a linear and negatively charged poly-
saccharide made of disaccharide repeating units of D-glucuronic
acid and N-acetyl-D-glucosamine which are linked by β-(1,3)
and β-(1,4) glycosidic bonds. HA is involved in several impor-
tant physiological and biological functions including protein
transport110 and regulation of water homeostasis.111 Moreover,
HA displays anti-inflammatory properties112 and has been
widely used as surgical aid in wound healing.113 HA has the
ability to form robust hydrogel networks and this property has
also been exploited, for instance, as a drug delivery system in
combination with other biopolymers such as hydroxypropyl
methylcellulose (HPMC), polyethylenimine (PEI) or
liposomes.114–117
Several articles have also described the use of liposomes in
combination with HA hydrogels (Fig. 8) for diﬀerent bio-
medical applications. For example, the eﬀect promoted by a
series of liposomes that depended on their net charge (i.e.,
neutral, positive or negatively charged), size, lipid concen-
tration and lipid composition was thoroughly studied in HA
hydrogels by Agnely and co-workers.115 The highest viscosity
and elasticity in HA hydrogels were observed when liposomes
were covered with polyethylene glycol chains. This induced
fast immobilization and a long residence time after injection.
Interestingly, despite this viscosity detected in these kinds of
hydrogels, all formulations were easily injectable by local
Fig. 7 (A) Illustration of a nanogel-coated liposome complex and
PEGSH used as a crosslinking agent. (B) Release proﬁles of the nanogel-
coated liposome from the hydrogel at diﬀerent pH values (pH 7.4 in
squares and pH 8.0 in diamonds). Adapted with permission from ref.
106. Copyright © 2012 Wiley-VCH.
Fig. 8 TEM micrograph of freeze-fractured hyaluronic acid hydrogels
containing liposomes. Adapted with permission from ref. 115. Copyright
© 2015 Elsevier.
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administration due to the shear-thinning behavior of the
formulation.
The combination between the HA polymer matrix and lipo-
somes has also contributed to the advance of some disease
treatments. For example, Miao and Huang118 improved osteo-
arthritis (OA) therapy by combining celecoxib (Clx), an analge-
sic and anti-inflammatory drug, with a mixture of liposomes
(SPC and Chol) that were embedded in HA hydrogels. This for-
mulation showed high encapsulation eﬃciencies and reduced
the adverse eﬀects induced by using Clx alone, such as gastro-
intestinal toxicities and high risk for cardiovascular events at
high doses. In vitro experiments confirmed the delay in the
liposomal Clx release when liposomes were part of the HA
structural framework. These preliminary results were also con-
firmed in vivo showing better eﬀectiveness of the liposomal
formulation than current Clx-treatments in both pain control
and cartilage protection.
HA is also a natural component of eye tissue, making it
ideal as a carrier for ocular drug delivery. In this area, Bochot
and co-workers119 developed a novel formulation consisting of
liposomes embedded in HA hydrogels for human uveitis, an
intraocular inflammatory disease of the uvea causing loss of
vision. In particular, the authors demonstrated that embed-
ding a vasoactive intestinal peptide (VIP), an immunosuppres-
sive agent, within a mixture of liposomes (ratio
PG : Chol : PEG : DSPE = 50 : 10 : 35 : 5) remarkably reduced
ocular inflammation signs in rats. Although the treatment
with VIP loaded in liposomes resulted to be less invasive than
surgical implantation, the liposomal formulation leakage
could reduce the eﬀectiveness for long-term treatments.
However, sustained drug release was clearly improved when
liposomal VIP was incorporated into HA hydrogels. This eﬀect
was observed in both in vitro and in vivo experiments with the
naked eye, thereby became a promising strategy for local
delivery.
In 2013, Venkatraman and co-workers120 studied the lipo-
somal release of latanoprost (Ltp), a drug used to reduce the
ocular pressure, by using two HA-based hydrogels. Before
loading the selected liposomes (EPC) in HA hydrogels, the bio-
polymer was first cross-linked with adipic dihydrazide (ADH)
and methacrylic anhydride (MA). The mechanical properties of
both systems were controlled by varying the cross-linking
degree, which clearly aﬀected the rheological and swelling pro-
perties of the hybrid systems. Remarkably, sustained release of
liposomal Ltp was accomplished over 90 days with a single
administration.
In the area of tissue engineering, Ying and co-workers121
have recently developed room temperature-liquid injectable
HA hydrogels based on a HA–tyramine (Tyr) conjugate contain-
ing horseradish peroxidase (HRP). HRP was embedded in a
mixture of two thermoresponsive liposomes (i.e., dipalmitoyl-
phosphatidylcholine (DPPC) and dimyristoylphosphatidyl
choline (DMPC)). Cholesterol was also introduced into the for-
mulation in order to modify the fluidity and reduce the un-
desirable HRP release at room temperature. The gelation
kinetic of the hybrid was found to depend on several factors
including lipid content, HA–Tyr concentration, sonication
time and composition of the liposome washing solution.
Injectability studies were carried out subcutaneously in a
mouse model. While the HA–Tyr/H2O2/HRP hybrid system
remained as a liquid at room temperature, the HRP release
upon injection promoted a reaction between HA–Tyr and
H2O2, inducing the formation of the cross-linked hydrogel
scaﬀold.
2.6. Alginate
Alginate (salt of alginic acid) is an anionic, high molecular
weight (500–2000 kDa) polysaccharide comprised of β-D-
mannuronate (M) and its C5-epimer α-L-glucuronate (G) resi-
dues, which are linked by β-1,4 glycosidic bonds. Alginate has
the ability to form hydrogel networks in the presence of divalent
cations and other cross-linking agents.122 A wide number of bio-
medical applications including wound healing, drug delivery or
tissue engineering have been extensively reported.123
In 1995, Rudolph and Monshipouri reported the first
example in which liposomes were encapsulated within an algi-
nate hydrogel.124 The authors used dipalmitoyl phosphatidyl-
choline liposomes as reaction sites for alginate hydrogelation.
As a model compound, cytochrome-c was embedded in these
large unilamellar liposomes and the release of liposome-
encapsulated alginate and calcium alginate beads was evalu-
ated. The authors found rapid drug release for both formu-
lations followed by a slower release rate for alginate beads
containing encapsulated liposomes. Around the same time,
Yotsuyanagi and co-workers125 described the factors aﬀecting
the loading and release of drug-containing liposomes in algi-
nate beads. The results obtained using 5(6)-carboxyfluorescein
(CF) as a model drug in liposomes of egg phosphatidylcholine
(EPC) and EPC/cholesterol (EPC/Cho) demonstrated that algi-
nate interacts with the liposomes causing a significant change
of permeability. Moreover, the presence of calcium ions
seemed to induce a higher drug-leakage than sodium ions.
Interestingly, a faster liposome release was observed when
using washed gel beads instead of fully-cured beads, showing
a proportional relationship between the release and the
erosion of the gel at high liposome concentrations.126 These
results suggested that the liposomes were not homogeneous
distributed through the gel beads but rather concentrated in
the central part. Such dependence between drug release and
the erosion of the alginate gel matrix was also observed by
Rongqing and co-workers.127 This group performed in vitro
and in vivo studies on the release of liposomes of L-α-phospha-
tidylcholine containingbee venompeptide,whichwere encapsu-
lated into calcium alginate gel beads coated with Eudragit
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S100 (methacrylic acid copolymer B). The results demonstrated
the potential of this formulation for colonic drug delivery.
In 2006, Wang and co-workers described128 the use of algi-
nate hydrogel microcapsules for the delivery of bovine serum
albumin (BSA) previously encapsulated in multivesicular lipo-
somes (MVLs) via a double emulsification process (water-in-
oil-in-water). In vitro release experiments indicated gradual lib-
eration of the BSA protein over a period of approximately
2 weeks without detecting any burst release eﬀect.
In 2010, Smith and co-workers reported the preparation of
alginate-loaded liposomes as a vehicle for the oral delivery of
bioactive proteins (i.e., alkaline phosphatase (ALP) as
model).129 The vesicles were prepared from the phospholipid
dipalmitoyl phosphatidylcholine using a simple dry film
hydration technique. On the other hand, the incorporation
of alginate in the liposomes enhanced their stability at
gastric pH.
More recently, Štěpánek’s group130 described the prepa-
ration of composite microparticles consisting of a calcium algi-
nate gel matrix with embedded liposomes made from
cholesterol : DPPC (dipalmitoylphosphatidylcholine) contain-
ing 5(6)-carboxyfluorescein. The authors demonstrated the
“on-demand” thermo-responsive release from liposomes when
embedded within the alginate hydrogel particles. The sensi-
tivity of the thermo-responsive system was found to depend on
the DPPC : cholesterol ratio and it was closely related to the
phase behavior of the lipid bilayer that formed the liposome.
The same group131 also prepared hydrogel microcapsules
(61 µm) containing fluorescent labelled liposomes having
yeast cells that worked as a biological trigger for controlled
opening of the microcapsules and consequent liberation of
sub-micrometer objects (dye). A similar formulation contain-
ing iron-oxide nanoparticles allowed the controlled release of
the dye by means of an alternating magnetic field (AMF)
(Fig. 9).132 A temperature increase above the phase transition
of the phospholipid bilayer was a necessary condition for the
functionality of the system. In spite of high SAR values of the
nanoparticles used, the rate of heat loss by conduction from
an individual microgel bead was too high to allow any signifi-
cant temperature rise to take place. The required temperature
rise could only be achieved in cases where the beads were
more concentrated or accumulated in a small volume.
Kim and co-workers133 reported the preparation of Janus-
compartmental alginate microbeads having two divided
phases of sensory polydiacetylene (PDA) liposomes and mag-
netic nanoparticles. The sensory liposomes were composed of
PDA for label-free signal generation and 1,2-dipalmitoyl-sn-
glycero-3-galloyl (DPGG) lipids whose galloyl headgroup has
specific interactions with lead(II) forming phenolic–metal com-
plexes, sensing this metal at concentrations as low as 0.1 mM
(∼20.7 ppm). In addition, about 45% of lead(II) ions could be
absorbed by hundred Janus microbeads in 4 h mainly due to
the interactions with the carboxylic acids of the alginate matrix
(they are around 200 times more present than those of the
lipids). The results show the recognition of lead(II) at the PDA
liposome surface by DPGG induced distortion of the conju-
gated yne–ene main chain of PDA, causing a color change
from blue to red as well as the development of red fluorescence
(Fig. 10). These microbeads have the additional advantage of
easy manipulation and convenient collection by applying an
external magnetic field.
The release study of a recombinant hepatitis B surface
antigen (HBsAg) was investigated by Cohen and co-workers.134
HBsAg was first encapsulated in liposomes made of a mixture
of phosphatidylcholine and cholesterol at a 1 : 1 molar ratio.
This carrier was successfully used as an adjuvant for BSA.
Liposomes containing HBsAg antigen were confirmed by cryo-
Fig. 10 Co-assembly of PCDA with DPGG to form PDA-DPGG lipo-
somes and a schematic illustration of the colorimetric lead(II) detection.
Reprinted with permission from ref. 133. Copyright © 2014 The Ameri-
can Chemical Society.
Fig. 9 (A) Carboxyﬂuorescein diﬀusion from LAMBs during an on–oﬀ
temperature program. DPPC : Chol ratio of 2 : 1. (B) AMF-induced release
of carboxyﬂuorescein from LAMBs in water at 50% dilution. Adapted
with permission from ref. 132. Copyright © 2013 The American Chemical
Society.
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TEM microscopy and were entrapped into alginate-poly-(L-
lysine) (PLL) hydrogel polymeric microspheres. Both in vitro
and in vivo experiments showed clear dependency of the
liposome release rate on the PLL molecular weight (i.e., lipo-
somes coated with PLL of 214 kDa produced higher liposomal
release than PLL of 25 kDa). These findings suggest the
eﬃciency of these hybrids as potential immunoadjuvants
because they reduce the amount of antigens and, hence,
may eliminate the number of shots necessary for optimal
vaccinations.
Oral delivery is another application in which alginate hydro-
gels have shown to be eﬃcient and robust systems even in the
presence of acid environments located in gastrointestinal
tracts. This robustness has been recently reported by Yuasa
and co-workers.135 These authors developed a liposomal for-
mulation made of DMPC, cholesterol and non-ionic surfactant
tween-20 at a 288 : 72 : 40 molar ratio, respectively, to entrap
manganese porphyrin (Mn-por), a superoxide dismutase
mimic that maintains the appropriate reactive oxygen species
(ROS) levels in cells (Fig. 11A). In order to protect the drug
from the gastrointestinal tract acid environment, the liposomal
formulation was embedded in alginate hydrogel fibers obtain-
ing hybrids of ca. 100 µm in diameter. Although encapsulation
eﬃciencies of Mn-por in liposomes were high (71%), this
eﬃciency diminished dramatically when liposome formulation
was embedded in the alginate matrix (3%). In vitro experi-
ments confirmed that both alginate hydrogels and liposomes
were able to maintain their physical properties under acidic
pH, allowing the delivery of Mn-por to the intestine retaining
the O2
•− inhibitory activity. The eﬃcacy of this system was also
evaluated in vivo by monitoring the tumor size in mice
(Fig. 11B). Interestingly, there was an inhibition of the tumor
growth when alginate fibers containing liposomes were orally
administered.
Very recently Deckers and co-workers136 have described the
preparation of barium crosslinked alginate microspheres
loaded with temperature sensitive liposomes (TSL/TSL-Ba-ms)
for embolization of blood vessels of tumors under mild
hyperthermia conditions. TSLs contained anti-cancer doxo-
rubicin and [Gd(HPDO3A)(H2O)] as contrast agents, which
were combined with holmium-containing microspheres
(Ho-ms) as a tracer agent (Fig. 12). In vivo monitoring was
carried out in the auricle VX2 tumor of a rabbit after intratu-
moral injection of a dispersion containing TSL-Ba-ms as well
as Ho-ms. The results showed that [Gd(HPDO3A)(H2O)] was
only released after applying mild hyperthermia (42 °C), indi-
cating that the TSLs are stable at 37 °C and do not leak their
loading.
2.7. Carrageenan
Carrageenan is a family of linear sulphated polysaccharides
made up of galactose repeating units and 3,6-anhydrogalactose
(3,6-AG) connected by α-1,3 and β-1,4 glycosidic linkages.
Some of these flexible macromolecules such as kappa (κ) and
iota (τ) carrageenans can adopt helical structures and promote
the formation of hydrogels in the presence of cations. Besides
its wide use in food industry as a thickening agent,137 a good
number of biomedical applications138 have also been
described involving carrageenan alone or in combination with
additional biopolymers like chitosan,139 alginate140 or
Fig. 11 (A) Mn-Ls/Alg represents an alginate hydrogel matrix containing
liposomes with embedded manganese porphyrin (Mn-Ls). (B) In vivo
anti-tumor eﬃcacy when Mn-Ls/Alg was administered orally. Compari-
son of the tumor volume in mice transplanted with Colon-26-cells.
Adapted with permission from ref. 135. Copyright © 2015 The Royal
Society of Chemistry.
Fig. 12 Schematic representation of temperature sensitive liposomes
(TSL) loaded in alginate microspheres crosslinked with barium ions (TSL
Bams). The TSLs are loaded with doxorubicin (DOX) and [Gd(HPDO3A)
(H2O)] (T1 MRI contrast agent). The DOX and [Gd(HPDO3A)(H2O)] are
released from the TSL-Ba-ms during mild hyperthermia. The release of
[Gd(HPDO3A)(H2O)] can be monitored by MRI. Empty alginate micro-
spheres crosslinked with holmium ions (T2* MRI contrast agent, Ho-ms)
are co-injected with TSL-Ba-ms to allow microsphere visualization by
MRI. Reprinted with permission from ref. 136. Copyright © 2015 Public
Library of Science.
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gelatin.141 However, the incorporation of liposomes into carra-
geenan hydrogels has been scarcely explored to date.
Recently, Kulkarni and co-workers142 have described the
combination of lipid vesicles and κ-carrageenan hydrogels for
sustained drug release applications. The strategy involved the
loading of a therapeutic drug in a liposomal formulation and
subsequent homogenization within the κ-carrageenan hydro-
gel. The final hybrid system was dehydrated to aﬀord hybrid
drug-loaded films (Fig. 13A), which were fully characterized by
Fourier transform infrared (FITR) spectroscopy and small-
angle X-ray scattering (SAXS). The release kinetics from both
native and lipid particles in hydrogel films were investigated
and monitored by UV-Vis spectroscopy. The results showed
that the drug encapsulation within the hydrogel allowed for
more eﬃcient protection of the drug and sustained release in
comparison to the native hydrogel in the absence of liposomes
(Fig. 13B).
In 2013, El-Menshawe and co-workers143 developed an
alternative to oral delivery systems by using topical adminis-
tration to improve anti-inflammatory activities and reduce
undesirable side eﬀects. Specifically, the authors described the
encapsulation of Meloxicam (MX), a non-steroidal anti-inflam-
matory drug, in niosomes based on a non-ionic surfactant
molecule and cholesterol at a 6 : 4 molar ratio. The corres-
ponding niosomal formulation was entrapped into two hydro-
gels: carrageenan and carboxymethyl-cellulose (CMC)
hydrogels. The results of the anti-inflammatory activities in
vivo clearly showed a decrease in the permeability when
increasing the cholesterol molar ratio. Consequently, this
enhanced the bioavailability of MX and, thereby, provided
better skin permeation.
2.8. Methylcellulose
Methylcellulose (MC) is a neutral derivative of cellulose, the
most abundant natural polysaccharide composed of (1 → 4)
linked β-D-glucopyranosyl units. In MC, methoxy groups substi-
tute the hydroxyls at the C-2, C-3 and/or C-6 positions of
anhydro-D-glucose units. MC is able to form hydrogels under
isothermal conditions when it is dissolved in hot water,144
being commonly used in food industry as a thickener and an
emulsifier as well as in several biomedical applications.145,146
Within the context of this review, Kapadia and co-
workers147 developed a novel approach to deliver acyclovir by
using niosomes that were entrapped into a mixture of MC and
carbopol. The final goal was to improve the poor bioavailability
exhibited by conventional ophthalmic solutions for treatment
of herpes simplex keratitis. Thus, acyclovir was encapsulated
in two niosomes based on two non-ionic surfactants (span 20
and span 60) and cholesterol at diﬀerent molar ratios. The
results showed that the drug encapsulation eﬃciency was
higher in the case of span 60. In vitro release experiments indi-
cated the suitability of the MC hydrogel as an eﬃcient vehicle
to deliver the drug in a controlled manner to the site of action
due to the presence of bioadhesive polymers in the formu-
lation. Moreover, the use of MC hydrogels containing nio-
somes helped us to reduce the toxicity that can be observed in
conventional therapies.
2.9. Xanthan gum
Xanthan gum (XG) is a polysaccharide composed of pentasac-
charide repeating units of glucose, mannose and glucuronic
acid in a 2 : 2 : 1 molar ratio. Besides its applications in food
industry as a stabilizer and thickening agent, XG has also been
used in some biomedical applications148 as a drug release
modifier due to its pH-responsive properties.
The mechanical properties of XG-based hydrogels can be
modulated upon blending with other biopolymers such as
locust bean gum (LBG) in a weight ratio of 1 : 1.149 The poly-
meric system LBG/XG was described by Carafa and co-
workers150 as a convenient drug delivery system for ibuprofen
and caﬀeine as model drugs. Firstly, these drugs were encapsu-
lated in non-ionic surfactant niosomes based on Tween-20 and
Fig. 13 (A) Lipid molecule made of a hydrophobic and a hydrophilic
part is stabilized by using Pluronic F127 upon ultrasonication. This
mixture is loaded containing a drug within the κ-carrageenan hydrogel.
(B) Release kinetic of the drug was monitored by UV-vis spectroscopy.
Drug release from native hydrogel ﬁlms (blue) and lipid particles within
hydrogel ﬁlms (red). Adapted with permission from ref. 142. Copyright ©
2015 Elsevier.
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Table 2 Summary of biopolymers used in the synthesis of liposome-encapsulated hydrogels for biomedical applications
Entry Biopolymer Chemical structure Ref.
1 Chitosan 70 and 74–84
2 Gelatin Mixture of peptides and proteins produced by partial hydrolysis of collagen 85–93
3 Dextran 101–103
4 Pullulan 106–109
5 Hyaluronic acid 115–121
6 Alginate 124–136
7 Carrageenan 142–143
8 Methylcellulose 147
9 Xanthan gum 149 and 150
Review Biomaterials Science
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cholesterol at a 1 : 1 molar ratio. As expected, a slight increase
in size was observed when model drugs were incorporated into
niosomes. However, no significant change in the surface
charge was detected. Interestingly, a diﬀerent behaviour in the
in vitro release was observed from both the niosome-hydrogel
matrix and the LBG/XG hydrogel without containing vesicles.
Consequently, caﬀeine, the more hydrophilic drug, was deli-
vered completely and much faster than ibuprofen, which was
capable to diﬀuse only 60% after 48 h. These findings revealed
the suitability of niosomes and LBG/XG hydrogels to be used
in topical applications due to the slow diﬀusion of the drugs
from the matrix and the protection of the noisome by the
hydrogel.
3. Summary and outlook
Biohydrogels (biopolymer-based hydrogels) have found numer-
ous uses across a wide range of food, pharmaceutical and bio-
medical industries, where their inherent properties of
biocompatibility and biodegradability play a key role. In the
area of drug release applications, many therapeutic molecules
have been successfully entrapped into diﬀerent biohydrogel
carriers (Table 2). However, one of the major concerns is the
rapid and uncontrolled release of the drug from the polymer
network (burst release), which may induce certain toxicity and
undesirable side eﬀects in biological systems. Over the last few
years, several strategies have been described to minimize the
burst release eﬀect including, among others, the use of lipo-
somes. In this particular approach, and before obtaining the
corresponding drug-in-liposome system, a number of para-
meters need to be optimized such as lipid composition,
particle size, morphology and surface charge in order to
eﬃciently encapsulate hydrophilic and/or hydrophobic mole-
cules. Remarkably, the protecting eﬀect provided by liposomes
to drugs can be further enhanced through their encapsulation
into hydrogel networks. In addition, the possibility of tuning
and obtaining either liposomes and/or hydrogels that can
respond to environmental stimuli (e.g., light, temperature, pH)
makes them ideal candidates for the fabrication of novel drug
delivery systems. Several kinds of biopolymer-based hydrogels
containing liposomes discussed in this review have proven
their eﬃcacy in controlled drug delivery and tissue engineering
applications.
These promising results may guide future development of
advanced mathematical models of controlled and burst release
profiles, providing a platform for the design of more eﬃcient
liposomal formulations for biomedical applications.
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